Compare IONQ Inc (IONQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IONQ Inc vs Recursion Pharmaceuticals Inc — how do they compare? IONQ Inc trades at $43.58 (market cap $17.60B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: IONQ Inc is far larger — about 9.7× Recursion Pharmaceuticals Inc's market cap, and IONQ Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| IONQ | RXRX | |
|---|---|---|
Market Cap | $17.60B | $1.81B |
Sector | Technology | Health |
52-Week High | $82.09 | $6.79 |
52-Week Low | $26.59 | $2.84 |
Enterprise Value | $15.53B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $43.92, up 3.27% today, with a bullish technical signal and strong revenue growth of 287% in Q2 2026. Despite significant net losses and negative margins, the company's backlog surged to $485 million, and it secured a $28 million defense contract extension. Analyst consensus is a Buy with a $73.33 price target, reflecting optimism about its quantum computing leadership.
Outlook: High growth potential in quantum computing with raised 2026 revenue guidance, but profitability remains distant. Risks include heavy cash burn, intense competition, and stock volatility. The stock offers speculative upside for growth investors tolerant of high risk.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IONQ Inc
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
